Voyager Therapeutics Inc.

**Signal Note: EcoR1 Capital Initiates $15.7M Position in Voyager Therapeutics** EcoR1's entry into VYGR signals confidence in the company's gene therapy pipeline, particularly VY-HTT01 for Huntington's disease, which is progressing toward late-stage development. This crossover investor's participation typically indicates near-term catalysts—likely IND clearance or clinical readout timing—though current visibility on Phase 2 data for the lead program remains limited. The position size (~4M shares) represents material conviction for a ~$600M market cap biotech with significant execution risk inherent to in vivo gene therapy programs.